Author's response to reviews

Title: Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Authors:

Denis Soulieres (denis.soulieres.chum@ssss.gouv.qc.ca)
Jose Luis Aguilar (joluagpo@hotmail.com)
Eric Chen (eric.chen@uhn.ca)
Krzysztof Misiukiewicz (krzysztof.misiukiewicz@mssm.edu)
Scott Ernst (Scott.Ernst@lhsc.on.ca)
Hyun Jung Lee (hjlap@hotmail.com)
Katherine Bryant (bryant_katherine_b@lilly.com)
Shuang He (he_shuang@lilly.com)
Coleman K Obasaju (obasaju_coleman_k@lilly.com)
Shao-Chun Chang (chang_shao-chun@lilly.com)
Steve Chin (chin_steve@lilly.com)
Douglas Adkins (dadkins@dom.wustl.edu)

Version: 2
Date: 20 April 2015

Author’s response to reviews:

As requested via email correspondence (17 April 2015), line numbering and minor changes to the order of the author’s contributions and acknowledgements sections have been made and are reflected in the currently submitted version.